Figure 4.

CDEAH inhibits the growth of PARP1-deficient xenograft tumors in nude mice. (A) Scheme of in vivo xenograft experiment. Four million cells of either WT HCT116 or PARP1-deficient HCT116 cells were subcutaneously injected into seven-week-old male nude mice. When the tumor size reached ∼200 mm³, vehicle (PBS) or CDEAH (6 mg/kg) was injected intratumorally every 3 days for 16 days. The mice were euthanized, followed by the indicated analyses. (B) Representative orthotopic xenografts of each indicated group (n = 3). (C) Tumor volume change was measured every 3 days for 16 days during drug treatment [n = 5, WT/PBS (black circle); 5, WT/CDEAH (gray square); 4, PARP1-deficient/PBS (gray triangle); 6, PARP1-deficient/CDEAH (pale gray inverted triangle)]. (D) Representative images of H&E, TUNEL and γ-H2AX staining of each dissected xenograft tumor. Data are presented as mean ± SEM.